You are here

Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.

Aapro M, Andre F, Blackwell K, Calvo E, Jahanzeb M, Papazisis K, Porta C, Pritchard K, Ravaud A.

Ann Oncol. 2014 Apr;25(4):763-73. 

Editors' comments: Dr. Ricardo Caponero

Everolimus has demonstrated substantial clinical benefits in breast cancer. Treatment-related adverse events include stomatitis, rash, infections, selected metabolic abnormalities, and noninfectious pneumonitis. Education of both physicians and patients is critical to achieving optimal everolimus exposure and clinical benefit as well as reducing the severity and duration of adverse events.